CRIS Key Statistics, Chart & Performance
The current stock price of CRIS is 1.06 USD. In the past month the price decreased by -15.2%. In the past year, price decreased by -67.38%.
CRIS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.34 | 406.46B | ||
| AMGN | AMGEN INC | 15.22 | 179.28B | ||
| GILD | GILEAD SCIENCES INC | 15.23 | 154.71B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.66 | 117.45B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.44 | 82.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 785.47 | 52.92B | ||
| INSM | INSMED INC | N/A | 37.94B | ||
| NTRA | NATERA INC | N/A | 32.26B | ||
| BIIB | BIOGEN INC | 10.58 | 25.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.22 | 21.84B | ||
| INCY | INCYTE CORP | 15.59 | 19.65B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About CRIS
Company Profile
Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. The company is headquartered in Lexington, Massachusetts and currently employs 33 full-time employees. The company went IPO on 2000-08-01. The firm is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). The Erivedge, is a commercialized orally administered small molecule Hedgehog signaling pathway antagonist. Its other clinical programs include Fimepinostat and CA-170. CA-170 is an oral small molecule drug candidate that targets V-domain Ig Suppressor of T-cell Activation, or VISTA, and PDL1 immune checkpoint proteins.
Company Info
CURIS INC
128 Spring Street, Building C, Suite 500
Lexington MASSACHUSETTS 02421 US
CEO: James Dentzer
Employees: 33
Phone: 16175036500
CURIS INC / CRIS FAQ
What does CRIS do?
Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. The company is headquartered in Lexington, Massachusetts and currently employs 33 full-time employees. The company went IPO on 2000-08-01. The firm is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). The Erivedge, is a commercialized orally administered small molecule Hedgehog signaling pathway antagonist. Its other clinical programs include Fimepinostat and CA-170. CA-170 is an oral small molecule drug candidate that targets V-domain Ig Suppressor of T-cell Activation, or VISTA, and PDL1 immune checkpoint proteins.
Can you provide the latest stock price for CURIS INC?
The current stock price of CRIS is 1.06 USD. The price increased by 0.95% in the last trading session.
Does CURIS INC pay dividends?
CRIS does not pay a dividend.
How is the ChartMill rating for CURIS INC?
CRIS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists CRIS stock?
CRIS stock is listed on the Nasdaq exchange.
What sector and industry does CURIS INC belong to?
CURIS INC (CRIS) operates in the Health Care sector and the Biotechnology industry.
Can you provide the growth outlook for CURIS INC?
The Revenue of CURIS INC (CRIS) is expected to grow by 17.66% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
CRIS Technical Analysis
CRIS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CRIS. CRIS has a bad profitability rating. Also its financial health evaluation is rather negative.
CRIS Financial Highlights
Over the last trailing twelve months CRIS reported a non-GAAP Earnings per Share(EPS) of -3.67. The EPS increased by 53.01% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -132.25% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
CRIS Forecast & Estimates
11 analysts have analysed CRIS and the average price target is 14.28 USD. This implies a price increase of 1247.17% is expected in the next year compared to the current price of 1.06.
For the next year, analysts expect an EPS growth of 63.06% and a revenue growth 17.66% for CRIS